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Abstract The article presents the hypothesis that nigro-
striatal dopamine may regulate movement by modulation
of tone and contraction in skeletal muscles through a
concentration-dependent inﬂuence on the postsynaptic D1
and D2 receptors on the follow manner: nigrostriatal axons
innervate both receptor types within the striatal locus so-
matotopically responsible for motor control in agonist/
antagonist muscle pair around a given joint. D1 receptors
interact with lower and D2 receptors with higher dopamine
concentrations. Synaptic dopamine concentration increases
immediately before movement starts. We hypothesize that
increasing dopamine concentrations stimulate ﬁrst the D1
receptors and reduce muscle tone in the antagonist muscle
and than stimulate D2 receptors and induce contraction in
the agonist muscle. The preceded muscle tone reduction in
the antagonist muscle eases the efﬁcient contraction of the
agonist. Our hypothesis is applicable for an explanation of
physiological movement regulation, different forms of
movement pathology and therapeutic drug effects. Further,
this hypothesis provides a theoretical basis for experi-
mental investigation of dopaminergic motor control and
development of new strategies for treatment of movement
disorders.
Keywords Dopamine  Movement  Parkinson’s disease 
Dyskinesia  Treatment
Introduction
Goal-directed movement is a composite behavioral action,
and the ascendant nigrostriatal dopaminergic system plays
an important role in movement regulation (Obeso et al.
2008). Nigrostriatal dopamine regulates movements by the
inﬂuence on the postsynaptic dopamine receptors expres-
sed by striatal neurons (Smith and Villalba 2008). The
striatal neurons express two types of receptors accepting
the nigrostriatal dopaminergic input, D1 and D2 (Bertran-
Gonzalez et al. 2008). Genetically transformed mice with
knocked-out genes for D1 or D2 receptors and normal
species with pharmacologically induced blockade of these
receptors reveal severe movement disorders indicating that
both types of receptors are important for movement regu-
lation (Sealfon and Olanow 2000). Some authors propose
that D1 and D2 receptors may play differential roles in
movement regulation, and their stimulation may cause
different motor effects (Walters et al. 2000). However, the
experimental design for separate assessment of differential
motor effects induced by selective D1 or D2 stimulation is
currently unsettled. The planning of experimental designs
for investigation of differential motor effects associated
with either D1 or D2 stimulation requires hypotheses about
the speciﬁc motor effects separately induced by selective
stimulation of either D1 or D2 receptors.
Based on recent data regarding the physiology of post-
synaptic nigrostriatal D1 and D2 dopamine receptors, we
hypothesize how D1 and D2 receptors participate in
movement regulation and suggest speciﬁc motor effects
related to each type of receptor. This hypothesis provides a
theoretical basis for planning experimental designs to
investigate movement regulation and to explain several
motor phenomena seen clinically. Experiments based on
this hypothesis may lead to the discovery of new treatment
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disorders.
Nigrostriatal projections and movement regulation
Nigrostriatal projections play an important role in move-
ment control. These projections consist of axons arising
from nigral cells. The microelectrode studies indicate that
the same single nigral cell is active during movements
around a given joint, both when agonists are predominant
and induce ﬂexion movements as well as when antagonist
muscle activation predominates to induce extension
(Schultz et al. 1983; Crutcher and DeLong 1984). A lesion
of nigral neurons leads to simultaneous dysfunction of
agonist and antagonist muscles in animal models of par-
kinsonism (Stern 1966) and idiopathic PD (Hoefer and
Putnam 1940). Similarly, punctuate and highly localized
striatal lesions also cause a simultaneous dysfunction in
agonist and antagonist muscle after stereotactic damage
(Hore and Vilis 1980; Kato and Kimura 1992) or striatal
neurotoxin administration (Wardas et al. 1999). These data
indicate that the single nigrostriatal projection simulta-
neously inﬂuences the pool of striatal neurons responsible
for motor activity in both muscles of agonist–antagonist
muscle pair.
The terminals of single nigrostriatal axons have a high
degree of arborization. The branches of the single nigral
projection innervate both striosome and matrix compart-
ments of the striatum (Gerfen et al. 1987). The terminal
arborization from a single axon usually covers a striatal
volume extending 1.5–2.0 mm rostrocaudally, 0.7–1.0 mm
dorsoventrally and 1.0–1.5 mm mediolaterally to supply
1.12 mm
3 of striatal volume (Matsuda et al. 2009) that
respects approximately 75,000 of striatal neurons (Oors-
chot 1996). These nigral axons transport dopamine to the
striatum. The released nigrostriatal dopamine regulates
movements by the action on two types of G protein-cou-
pled postsynaptic dopamine receptors, D1 and D2 (Bloch
et al. 2003). These receptors differ in their chemical
structure, interaction with intracellular signal systems,
pathways of signal transduction toward other neural
structures, characteristics of coding genes, evolutionary
origin, and independently acquired mechanisms of dopa-
mine binding (Callier et al. 2003).
The mapping of D1 and D2 receptors reveals a high
density of both receptors in the striatum and overlapping of
their distribution in both striosome and matrix compart-
ments of striatum (Boyson et al. 1986; Dewar and Reader
1989; Hersch et al. 1995). Thus the single nigral axon may
inﬂuence both D1 and D2 receptors in the pool of striatal
neurons responsible for movement activity of agonist–
antagonist muscle pair. This integrated dopaminergic
control involves two dopamine-dependent effects occur in
skeletal muscle during movement: acceleration of con-
traction in an agonist and tone reduction (reduced resis-
tance to passive stretch) in an antagonist (Takakusaki et al.
2003). Experimentally, the acceleration of agonist con-
traction increases in response to dopaminomimetics and
decreases with dopamine antagonists (Meintzschel and
Ziemann 2006). At a clinical level, this parallelism can be
seen with nigrostriatal dopamine depletion that leads to
parkinsonism, characterized by coexistent brady- or hypo-
kinesia with decreased acceleration of agonist muscle
contraction and rigidity or tone increase (Verhave et al.
2009); in contrast, striatal dopamine excess is modeled
clinically as coexistent hyperkinesia and muscle hypotonia
(Rylander et al. 2009).
The interaction between dopamine and striatal D1- and
D2-receptors occurs simultaneously with tone and con-
traction modulation during movement leading one to con-
sider that D1 and D2 may be distinguished in tone and
contraction regulation on the follow manner:
Dopamine-dependent tone and contraction regulation
D1 and D2 receptors express distinct patterns of afﬁnity to
dopamine and interact differently with one another
depending on synaptic concentrations of neurotransmitter
(Zheng et al. 1999; Gerlach et al. 2003). The nanomolar
concentrations of dopamine interact preferentially with D1
receptors (dissociation constant 740 nM (Niznik et al.
1986, p. 8401), whereas micromolar concentrations are
needed for prominent D2 receptor activation (dissociation
constant 117 lM (Gerlach et al. 2003, p. 1123). The
nanomolar or micromolar dopamine concentrations are
detected in different behavioral motor patterns. The nano-
molar dopamine concentrations are detected at rest
(Abercrombie et al. 1989). The micromolar concentrations
are associated with volitional movement activity (Hattori
et al. 1994; Murphy et al. 2001).
Both resting nanomolar and movement-associated
micromolar dopamine concentrations are depleted in PD
(Hefti et al. 1980; Schwarting and Huston 1996; King and
Finlay 1995) and have behavioral correlates. At rest, there is
disinhibited muscle tone manifested as muscular rigidity, a
phenomenon that is associated with pathologically reduced
resting nanomolar concentrations of dopamine acting at D1
nigrostriatal receptors. Thus one can hypothesize that
dopamine/D1 interaction regulates muscle tone. During
voluntary movements in PD, reduced acceleration of con-
traction occurs, manifested as bradykinesia, a phenomenon
that, according to our hypothesis, is associated with path-
ologically reduced micromolar dopamine levels acting at
D2 nigrostriatal receptors, so that the physiological role of
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tion of contraction. This assumption is conﬁrmed by the
evidence of D2 stimulation during voluntary movement
obtained from the PET studies in healthy humans and in PD
(Goerendt et al. 2003). The distribution of D1 and D2
receptors within the innervation ﬁeld of the singular
nigrostriatal axon enables simultaneous stimulation of both
receptors in the striatal locus somatotopically responsible
for motor control in agonist/antagonist muscle pair around
the given joint. Thus both D1-mediated muscle tone inhi-
bition and D2-accelerated contraction may be synchroni-
cally regulated during movement in the antagonist muscle
pair.
Our hypothesis may explain the regulation of movement
release in healthy humans.
Implication for normal movement release
The dopamine concentration rises in the synapse during
movement initiation from resting nanomolar to move-
ment-associated micromolar level. The increasing nano-
molar dopamine concentration saturates D1 receptors and
causes an inhibition of muscle tone in complementary
antagonist muscle (down-regulation). The maximal D1
mediated tone reduction occurs as all D1 receptors are
saturated. Voluntary movement is associated with nigro-
striatal dopamine release and rise of its concentration in
the nigrostriatal synapse (Goerendt et al. 2003). During
the rise of dopamine concentration the D1 receptors
interact with lower dopamine concentrations than D2 so
that the D1-mediated tone inhibition must occur before
D2-promoted acceleration of contraction. The earlier D1-
induced tone inhibition decreases the tonic resistance of
antagonist muscle and eases the contraction of agonist
muscle. The further rising dopamine concentration
reaches the level that interact with D2 receptors and
accelerates contraction of an agonist muscle (up-regula-
tion). As dopamine concentration is rising further, more
D2 receptors became stimulated and acceleration is fur-
ther facilitated. The contraction is maximally accelerated
as all D2 receptors are stimulated. The accelerated con-
traction causes agonist movement in the given joint.
During D2 stimulation by micromolar dopamine concen-
tration the D1 receptors remain stimulated and the muscle
tone in antagonist remains inhibited. Quick movements
are maximized when tone in antagonist muscles is com-
pletely inhibited during maximal acceleration of agonist
contraction. Thus, normal movement release is affected
due to two dopamine-dependent integrated processes:
D2-accelerated contraction in agonist which is facilitated
by D1-inhibited tonic resistance in antagonist.
Implications for clinical movement disorders: rigidity
and bradykinesia
Our hypothesis of an integrative system that inﬂuences D1-
mediated tone inhibition and D2-accelerated contraction
depending on synaptic dopamine concentrations helps to
conceptualize pathophysiological mechanisms underlying
the clinical symptoms in several dopamine-related move-
ment disorders. Several dopamine-related movement dis-
orders are associated with impaired transmitter/receptor
interaction. These disorders are brieﬂy presented from the
perspective of the proposed hypothesis.
Reduced dopamine synthesis: idiopathic Parkinson’s
disease
In this dopamine depleted pathological situation, when
resting dopamine levels in the striatal synaptic cleft are
below the baseline normal low nanomolar levels, tone
cannot be sufﬁciently inhibited in the D1-dependent system
leading to a resting state of hypertonicity and clinical
appearance of muscular rigidity. Additionally, as move-
ment starts, the requisite micromolar dopamine levels for
normal motor activation are not reached at the D2 system
leading to reduced capacity to generate movement (bra-
dykinesia). Without dopaminergic restorative therapy, the
progressive loss of dopamine production and release leads
to increasingly impaired D1 and D2 stimulation and
worsening of rigidity and bradykinesia in the course of
disease.
Parkinson-associated motor phenomena: the Froment
sign
Our hypothesis explains also the Froment sign: tone aug-
mentation when the contralateral limb moves voluntarily,
ﬁrst reported by Froment in the 1920s and newly reviewed
in reference to PD (Broussolle et al. 2007). Voluntary
movement induces proprioceptive stimulation that triggers
compensatory physiological mechanisms involving pos-
tural responses (Kristeva-Feige et al. 1996; Caudron et al.
2008). Similar to the Froment sign in PD, movement-
induced proprioceptive stimulation in healthy humans is
associated with contralateral tonic EMG burst activity in
the resting limb (Baldissera et al. 2008). This EMG activity
is thought to be the postural response induced by propri-
oceptive sensorimotor mechanisms, termed the anticipatory
postural adjustment (Massion et al. 1999). This postural
response is not clinically detectable in healthy humans but
becomes clinically signiﬁcant as the Froment Sign in PD as
a reﬂection of a hyperactive postural response and the
appearance of hypertonicity (rigidity).
Dopaminergic movement regulation 1361
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dopamine depleted conditions like MPTP-treated monkeys
(Filion et al. 1988) or subjects with idiopathic PD (Val-
kovic et al. 2006). We suggest that the Froment sign
develops as a disinhibited anticipatory postural adjustment
consequent to the nigrostriatal dopamine deﬁciency. Our
hypothesis helps to explain the Froment sign. Our premise
is that dopamine/D1 interaction reduces muscle tone, and
the muscular hypertonicity in PD is the consequence of
insufﬁcient interaction between pathologically reduced
resting nanomolar dopamine level and D1 receptors. With
the beginning of voluntary movement involving the con-
tralateral body region, this deﬁcient dopamine/D1 system
receives proprioceptive inputs from postural afferents with
bilateral inﬂuences on the basal ganglia. These afferents
induce greater reduction of dopamine/D1 interaction than
the resting situation. We suggest that the greater reduction
of dopamine/D1 interaction may be caused by further
impairment of presynaptic dopamine release by one or
more of several neurotransmitters that are activated by
proprioreceptive mechanisms with inﬂuences on presyn-
aptic nigrostriatal dopaminergic terminals. Putative neu-
rotransmitters include GABA and endogenous endorphins
(Ronken et al. 1993; Di Chiara and Imperato 1988;
Spanagel et al. 1992) which have both been shown to
inﬂuence the sensorimotor processing in the striatum and
substantia nigra (Bevan et al. 1996; Johnson and Napier
1997; Ramanathan et al. 2002). Thus, the proprioceptive
stimulation that occurs with voluntary activation of the
contralateral extremity may cause an acute inhibition of
presynaptic dopamine release which behaviorally translates
into the appearance or enhancement of rigidity in a par-
kinsonian patient already suffering from dopamine deple-
tion. In the patient without apparent rigidity on the side
being tested, this activation procedure can induce rigidity
that was not apparent without the activation procedure; in
the patient with bilateral rigidity at rest, the activation
procedure enhances the rigidity through the same putative
mechanism.
Parkinson-associated motor phenomena: freezing
This proprioceptive involvement may be also hypotheti-
cally applicable to parkinsonian freezing or gait blockade.
During freezing the patient attempts to step forward but
cannot move his legs. In parallel to our explanation of the
Froment sign, the attempt to move one leg leads to pro-
prioceptive stimulation of postural responses for the con-
tralateral leg that is used for support and stabilization. This
proprioceptive stimulation induces a sudden inhibition of
dopamine release on the side of the brain controlling the
foot that is being moved forward. Inhibited dopamine
release causes diminished D1 stimulation, and as a
consequence, muscle tone acutely increases. As dopamine
release is acutely impaired, synaptic concentration cannot
achieve a level necessary for micromolar D2 activation.
Without D2 activation, acceleration of contraction is
blocked, movement acceleration cannot occur, and step-
ping fails.
Our explanation of freezing is supported by the obser-
vation that levodopa only poorly improves this symptom: if
release is blocked, dopamine cannot act even if it is present
inside the presynaptic nigrostriatal terminals. Instead,
amantadine is sometimes effective against freezing (Singer
et al. 2005), and its effects may be explained by the an-
tiglutamatergic non-dopaminergic action of this drug
(Blanchet et al. 1998). Also the extracellularly acting
MAO-B-inhibitor rasagiline was shown to have a positive
effect against freezing (Coria and Cozar-Santiago Mdel
2008), and according to our hypothesis, this observation
would be explained by the enhanced dopamine remaining
in the synaptic cleft consequent to this drug’s extracellular
effects.
Postsynaptic receptor blockade: neuroleptic induced
parkinsonism
Neuroleptic treatment may be associated with the occur-
rence of parkinsonian signs, including rigidity, bradykine-
sia, tremor, and gait impairment. Radionuclide
neuroimaging investigations in subjects with neuroleptic
induced parkinsonism document postsynaptic striatal
dopamine receptor blockade (Knable et al. 1997) con-
ﬁrming that these drugs interrupt the dopamine/dopami-
nergic striatal receptor interactions. In this case, however,
dopamine production and release remain undisturbed or are
even overactive, although dopamine cannot bind on post-
synaptic sites because of neuroleptic receptor blockade.
Different drugs known to induce neuroleptic-associated
parkinsonism share the properties of binding to both D1
and D2 receptors (Reimold et al. 2007). According to the
model proposed, failed dopamine/D1 interaction from
receptor blockade leads to the disinhibition of muscular
tone and the clinical appearance of rigidity, whereas
interrupted dopamine/D2 interaction disables the acceler-
ation of muscle contraction, causing slowness of movement
or bradykinesia.
Postsynaptic dopaminergic receptor degeneration:
atypical parkinsonism (progressive supranuclear palsy,
multisystem atrophy of parkinsonian type, cortico-basal
degeneration)
Atypical parkinsonism is characterized by degeneration of
postsynaptic striatal cells and reduced density of postsyn-
aptic dopamine receptors (Piccini and Whone 2004). The
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to insufﬁcient effects of dopamine stimulation. In some of
these conditions, nigrostriatal dopaminergic cell loss also
occurs, leading to low dopamine levels as well. In the
proposed hypothesis, impaired D1 activation lead to tone
disinhibition and muscular rigidity, whereas impaired D2
effects induce diminished acceleration of muscle contrac-
tion and bradykinesia.
Taken together, all three forms of diminished transmit-
ter/receptor interaction—presynaptic, synaptic and post-
synaptic—result in increased tone and impairment of
volitionally generated movements.
Implications for clinical hyperkinetic movement
disorders: involuntary movements
The hypothesis of an integrative system that inﬂuences D1-
mediated tone inhibition and D2-accelerated contraction is
also applicable for explanation of disorders with excessive
involuntary movements.
Levodopa-induced dyskinesia
Levodopa-induced dyskinesia (LID) occurs in progressive
stages of PD when nigrostriatal terminals are decreased in
numbers and poorly store dopamine (Del Sorbo and Alb-
anese 2008). Once dopamine is released into the synaptic
cleft its interaction with postsynaptic sites escapes normal
physiological control mechanisms. Uncontrolled dopami-
nergic activity with increased synaptic dopamine level
overstimulates both the nanomolar responsive D1 receptors
and the micromolar responsive D2 receptors. According to
our hypothesis, the excessive stimulation of D1 receptors
facilitates the tone inhibition leading to muscular hypotonia
and reduction of tonic antagonist resistance. The reduced
antagonist resistance and additional excessive D2 stimu-
lation can lead to uncontrolled acceleration of contraction
in agonist muscle and involuntary movement release. Our
model is also in concert with the observation that D1
agonists induce dyskinesia in rodents with lesioned sub-
stantia nigra (Taylor et al. 2005) and D1-antagonist may
prevent LID. According to our model, D1 antagonists
inhibit dopamine/D1 interactions, so that dopamine cannot
realize its action on D1 receptors and cannot cause tone
reduction. Therefore, muscle tone increases. If dopamine/
D1 interaction is strongly interrupted over prolonged time
period, one can consider that muscle tone may increase as
an ambient clinical state. The increased tone works against
contraction of agonist muscles and may inhibit volitional
and non-volitional movements. In this way, the generation
of dyskinesia may be prevented. The opposite situation
occurs if D1 agonist is given (Delﬁno et al. 2007), in that
D1 receptors became overstimulated and muscle tone
decreases strongly. As muscle tone fails, the acceleration of
contraction has no resistance, and even with low levels of
ambient D2 stimulation, dyskinetic movement may
develop.
Levodopa-responsive dystonia (LRD)
Levodopa-responsive dystonia is a form of treatable dys-
tonia that is highly disabling unless patients receive levo-
dopa. Clinically the disorder appears as a ﬂuctuating
condition with early morning signs usually minimal, but
progressive slow involuntary movements with continuous
tonic muscle tension, painful twisting (dystonia) and
pathologic dystonic posture as the day progresses. The
acceleration of contraction and voluntary movement
release are not affected. LRD is usually responsive to
treatment with low dose of levodopa with complete or
nearly complete resolution of signs and symptoms.
According to our model, the pathologic tone disinhibition
may be a consequence of impaired dopamine/D1 interac-
tion. The considered impaired dopamine/D1 interaction is
conﬁrmed by treatment efﬁcacy of very low doses of
levodopa, because low dosage treatment increases the D1-
interacting nanomolar dopamine levels and restores the
normal tone inhibition.
The voluntary agonist contraction is not affected and
higher dosage of levodopa is not necessary for treatment,
indicating that dopamine/D2 interaction is not disturbed;
otherwise according to our model the disorders of volun-
tary contraction should be obtained. Drug-induced dyski-
nesia, typical of Parkinson’s disease and higher dosage
exposure to levodopa, is not typical for LRD.
Tics
Tics are typically rapid and repetitive involuntary move-
ments. They can occur in any muscle group and often
ﬂuctuate in severity and change from body part to body
part over time. Tone is not affected in tic disorders, even in
the anatomic areas afﬂicted by tics. The functional neuro-
imaging revealed an increased postsynaptic D2 receptor
density in striatum (Wong et al. 2008) indicating that these
receptors may be involved in the pathogenesis of tics.
According to our hypothesis, the increased density of
postsynaptic striatal D2 receptors may suggest the over-
active dopamine/D2 interaction leading to involuntary
acceleration of contraction and involuntary movement
release. The D1 system remains intact, therefore muscle
tone is not altered in the affected muscles. This view is
conﬁrmed by the fact that intake of D2 antagonist halo-
peridol can resolve tics in some patients (Shprecher and
Kurlan 2009), whereas the intake of D1 antagonists did not
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Handley 1999).
The following table summarizes the changes of nigro-
striatal dopamine concentration, dopamine/receptor inter-
action and clinical motor characteristics in healthy humans
and movement pathology (Table 1).
Discussion
Normal voluntary movement is controlled from different
regulation levels. With our model, we hypothesize that
dopamine-dependent movement regulation at the nigro-
striatal level occurs by modulation of tone and contraction
in skeletal muscles through the action of nano- or micro-
molar dopamine concentrations on the postsynaptic D1 and
D2 receptors. We posit that synaptic dopamine concen-
tration sequentially rises during movement from nanomolar
D1-interacting to micromolar D2-interacting levels and
ﬁrst inhibits muscle tone through D1 receptors and then
accelerates muscle contraction to induce normal movement
through D2 receptors. Our model suggests that tone inhi-
bition in antagonist muscles precedes the activation of
agonist muscles. The same nigrostriatal axons simulta-
neously innervate the agonist/antagonist muscle pairs so
that the consecutive stimulation of D1 and D2 receptors
enables the synchronized D1-mediated tone inhibition and
D2-promoted acceleration of contraction in the antagonist
muscle pair.
This model is useful for the explanation of normal
movement regulation and different forms of movement
pathology. Our suggestion of preceding antagonist inhibi-
tion before agonist activation during nigrostriatal move-
ment regulation needs experimental conﬁrmation.
Although such studies have not yet been performed, cor-
tically based experiments with transcranial magnet stimu-
lation conﬁrm that surround inhibition characterized by
antagonist inhibition occurs prior to agonist activation at
the cortical level of movement regulation (Shin et al. 2009;
Beck et al. 2008; Richardson et al. 2008; Voller et al. 2005,
2006; Sohn and Hallett 2004). Thus, a parallel system at
the striatal level is logical, though not yet speciﬁcally
tested. The key experiments to conduct would involve
testing whether rising dopamine concentration ﬁrst inhibits
the muscle tone in antagonist muscle by nanomolar action
on D1 receptors and then accelerates contraction in agonist
by micromolar action on D2 receptor. The innervation of
both D1 and D2 receptor by the singular nigrostriatal axon
within the nigrostriatal locus responsible for movement
control in both agonist and antagonist muscle around the
given joint makes our hypothesis both plausible and test-
able and provides a theoretical framework for experimental
studies both in a laboratory and clinical arena. Below we
highlight suggested experiments to investigate and thereby
conﬁrm or refute our hypothesis. The studies on the healthy
humans are of particular interest because the changes in
central movement regulation during voluntary motor tasks
during inﬂuence on D1 or D2 receptors may be assessed
electrophysiologically, kinematically and dynamically.
Studies in human motor cortex electrophysiology
The changes of motor cortex excitability assessed by
transcranial magnetic stimulation have been obtained after
intake of dopaminomimetics (Korchounov et al. 2007) and
switching-on deep brain stimulation of subthalamic
nucleus (Cunic et al. 2002;P o ¨tter-Nerger et al. 2008).
These data indicate that changes in nigrostriatal dopami-
nergic transmission may be reﬂected and measured at the
level of motor cortex. According to our model, D1 or D2
agonists may improve motor parameters. As reduced sur-
round inhibition was shown to be associated with disturbed
movement release and occurrence of dystonia (Beck et al.
2008), in opposite the enhanced surround inhibition may be
assumed to improve movement realization. Therefore one
may expect that the increased surround inhibition may
Table 1 Changes of nigrostriatal dopamine concentration, dopamine/receptor interaction and clinical motor characteristics in healthy humans
and movement pathology
Free synaptic
dopamine
concentration
Dopamine/D1
interaction
Muscle tone
in antagonist
Dopamine/D2
interaction
Acceleration of muscle
contraction in agonist
Rest in healthy human Low Normal Normotonic Not present Not present
Movement in healthy human Increased Increased Reduced Normal Normal (physiologic movement)
Idiopathic (presynaptic) PD Reduced Reduced Increased (muscular rigidity) Reduced Reduced (bradykinesia)
Neuroleptic PD Normal Reduced Increased (muscular rigidity) Reduced Reduced (bradykinesia)
Atypical (postsynaptic) PD Normal Reduced Increased (muscular rigidity) Reduced Reduced (bradykinesia)
Levodopa-induced dyskinesia Normal/Increased Increased Reduced Increased Increased (hyperkinesia)
Levodopa-responsive dystonia Normal Reduced Increased Normal Normal (physiologic movement)
Tics Normal Normal Normotonia Increased Tics
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trary, the intake of D1 or D2 antagonists may be assumed
to decrease the surround inhibition. The technical question
is, if the solely intake of D1 ligands will inﬂuence only
antagonistic part of surround inhibition whereas the solely
intake of D2 ligands will exclusively inﬂuence the agonist
part of surround inhibition. According to our model the
diminished surround inhibition may be expected in PD and
reverse after switch on deep brain stimulation of subtha-
lamic nucleus. Further our hypothesis predicts the profound
fall of motor cortical surround inhibition ipsilateral to the
moving hand (facilitation) in PD, providing a basis for the
Froment sign. According the previous studies, the short
intracortical inhibition may be assumed to be disturbed
contralaterally to increasing muscle tone during Froment
maneuvre (Voller et al. 2006).
Studies in human functional neurovisualization
Our hypothesis suggests a different role of D1 and D2
receptors in movement regulation. PET techniques enable
assessment of both D1 and D2 receptors in vivo in humans
(Andrews et al. 1999). According to our hypothesis as
movement starts, dopamine ﬁrst saturates D1 and then D2
receptors. Such sequential saturation should be seen in PET
if the investigated subjects perform a motor task associated
with nigrostriatal dopamine release. PET studies can be
planned in two steps: in the ﬁrst session the patients per-
form a motor task after intake of D1 ligand (for example,
[
11C]SCH23390). It could be expected that immediately
before movement starts, the reduction of ligand binding
will occur, because releasing dopamine will displace the
ligand from the receptor. The time curve of displacement
start and maximal displacement should be registered. In the
second session the same motor task may be performed after
intake of D2 ligand (for example, [
11C]raclopride).
According to our model the already known displacement of
[
11C]raclopride from D2 receptors after movement starts
(Goerendt et al. 2003) should occur later than the dis-
placement of D1 ligand.
Additionally our hypothesis suggests that in patients
with PD with strong unilateral muscular rigidity the bind-
ing of D1 ligands in PET will be asymmetric and increased
contralaterally to the more rigid body side.
Performing the electrophysiological investigations and
PET studies using the same motor tasks may show the
preceding antagonist inhibition in both neurovisualizative
and electrophysiological examinations. If so, it may be a
strong argument that the inhibition of antagonistic mus-
cular activity during movement is the common principal of
central movement regulation at nigrostriatal and cortical
regulation levels although exact neurotransmitter mecha-
nisms may differ.
Animal studies
D1 or D2 knock-out mice may serve as reasonable animal
models of striatal function, although no model has been
developed that selectively knocks out one or the other set
of receptors in the striatum without involvement of other
dopamine systems in the brain (Sealfon and Olanow 2000).
As a ﬁrst step, however, the currently available knock-out
models can be used to investigate our hypotheses and to
establish the locomotor effects of selective D1 and D2
ligands.
The mentioned studies are able to be performed in living
moving objects because our hypothesis is functionally and
clinically oriented. Our model provide the explanation of
mechanisms enabling the realization of the goal-directed
movement and may sufﬁciently extend the actual under-
standing of the role of basal ganglia in regulation of
movement sequences and adaptive aspects of movements
(Doyon 2008).
Our model is based on recent ﬁndings and statements
that (Obeso et al. 2008) nigrostriatal somatotopy is orga-
nized as the same nigrostriatal projections innervate the
antagonist muscle pairs around the same joint (Smith and
Villalba 2008); postsynaptic functionally active D1 and D2
dopamine receptors are simultaneously innervated by the
singular nigrostriatal axon within the striatal locus so-
matotopically responsible for motor control in agonist/
antagonist muscle pair around the given joint (Bertran-
Gonzalez et al. 2008); D1 receptors interact with nano-
molar and D2 with micromolar concentration of dopamine.
All these points are not considered by the previous models.
In our study, we used data based on direct measurements of
dissociation constants for dopamine and its receptors.
These assessments reﬂect exact interactions between
dopamine and its binding sites, and such techniques largely
replace analytic methods such as microdialysis (Chaurasia
et al. 2007).
The previous models of basal ganglia disorders are
primarily based on anatomical ﬁndings. They differ from
ours and have not been able to explain the intimate
behavioral interaction between tone and muscle contraction
in normal movement or in striatal dopaminergic disorders
as Parkinson’s disease and various forms of involuntary
movements (Wichmann and DeLong 1996). Those models
have come under question because of signiﬁcant discrep-
ancies between the predictions and the observed outcome
following lesions of speciﬁc nuclei and because of basic
questions regarding the anatomic substrate of the models.
For example, anatomically the degree of segregation of the
basal ganglia–thalamocortical circuits has been questioned
(Percheron et al. 1984; Lynd-Balta and Haber 1994;
Hedreen and DeLong 1991; Percheron and Filion 1991)
and the existence of the proposed indirect pathway through
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123the STN has been challenged (Parent and Hazrati 1995a,
b). It has also been proposed that GPe may provide another
output from the basal ganglia via projections to the retic-
ular nucleus of the thalamus (Hazrati and Parent 1994;
Asanuma 1994). The notable and obvious discrepancies of
previous models are the failure of thalamic lesion to pro-
duce clear akinesia/rigidity (Burchiel 1995) and the lack of
predicted disturbances of voluntary movement and the
expected abolition of dyskinesias by GPi lesions (DeLong
and Georgopoulos 1981; Baron et al. 1996; Dogali et al.
1995; Laitinen 1995; Lozano et al. 1995). In addition, GPe
lesions do not appear to reduce drug-induced dyskinesias,
as predicted by the model (Blanchet et al. 1994). Some of
these discrepancies have been subject of recent articles and
reviews (Albin 1995; Chesselet and Delfs 1996). Also
these models are not able to provide the explanation of
parkinsonian symptoms and drug effects, which are done
by our hypothesis.
Limitations of our model
Although our model provides the explanation for different
motor phenomena, it has also limitations. The model is
developed in the context that bradykinesia and rigidity are
hallmark features of PD. In the statistically based factor
analysis of the UPDRS, rigidity and bradykinesia are sep-
arate as distinct features, possibly suggesting that their
physiological bases may not be linked. According to our
hypothesis rigidity appears due to diminished dopamine/D1
interaction whereas bradykinesia is a consequence of
reduced dopamine/D2 interaction. On the other hand, no
clinical analysis of drug or surgical treatment has ever
reported a differential effect on bradykinesia versus rigid-
ity, suggesting that improvements may necessarily have a
shared physiological relationship.
The further limitation of our hypothesis is the missed
explanation of tremor. This limitation may be due to the
fact that we are dealing exclusively with dopaminergic
nigrostriatal transmission. The relationship between tremor
and dopamine is not clear. First, tremor often shows only
poor improvement after levodopa treatment indicating that
this symptom of PD is only partially dopamine dependent.
Second, three forms of parkinsonian tremor are described
and it is not clear, whether each forms underlie the same
neurotransmitter disorder (Deuschl et al. 2001). Third, the
patients with a tremor-dominant and akinetic-rigid form of
PD express different neurochemical and neuropathological
changes. So the patients with a tremor-dominant form show
predominant degeneration of the medial substantia nigra
and the retrorubral ﬁeld (A8), whereas in akinetic-rigid
patients, the lateral substantia nigra was mainly affected
(Hirsch et al. 1992; Jellinger 1999). This is also in agree-
ment with a neurochemical study that related region-
speciﬁc dopamine deﬁciencies to tremor-dominant as
opposed to akinetic-rigid forms (Bernheimer et al. 1973).
In humans, positron emission tomography (PET) studies
revealed that bradykinesia correlated best with nigrostriatal
D2 receptor deﬁciency (Vingerhoets et al. 1997) whereas
tremor-dominant patients showed increased metabolic rates
in thalamus and pons (Antonini et al. 1998). Thus, it is not
clear to what extent dopamine and tremor are related and
whether our model is applicable for explanation of tremor.
Future directions
This hypothesis is offered to prompt clinicians and labo-
ratory scientists to consider striatal dopamine receptor
interactions in more detail. The model is not all-inclusive,
but it provides a framework for testable experiments in
humans and experimental animals. At the molecular biol-
ogy and neuropharmacological levels, the hypothesis sug-
gests that putative treatments need to consider both D1 and
D2 activity for maximal therapeutic efﬁcacy in most
movement disorders.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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